Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer.

Martin Voss, Naheema Gordon, Stephanie Maloney, Raji Ganesan, L Ludeman, K McCarthy, R Gornall, G Schaller, Wenbin Wei, Fedor Berditchevski, Sudha Sundar

Research output: Contribution to journalArticle

43 Citations (Scopus)


Background:Type II cancers account for 10% of endometrial cancers but 50% of recurrence. Response rates to chemotherapy at recurrence are poor and better prognostic markers are needed to guide therapy. CD151 is a small transmembrane protein that regulates cell migration and facilitates cancer metastasis. High CD151 expression confers poor prognosis in breast, pancreatic and colorectal cancer. The prognostic significance of tetraspanin CD151 expression in poor outcome endometrial cancers was evaluated, along with oestrogen receptor (ER), progesterone receptor (PR), p53, human epidermal growth factor receptor -2 (HER-2), and CD 151 staining compared with α6β1, α3β1 integrins, and E-cadherin.Methods:Tissue microarray constructed from 156 poor outcome endometrial cancers, tested with immunohistochemistry and staining correlated with clinicopathological data were used. A total of 131 data sets were complete for analysis.Results:Expression of CD151 was significantly higher in uterine papillary serous and clear cell carcinoma than in grade 3 endometrioid carcinoma, sarcoma or carcinosarcoma (P
Original languageEnglish
Pages (from-to)1611-8
Number of pages8
JournalBritish Journal of Cancer
Issue number10
Publication statusPublished - 10 May 2011


  • tetraspanin
  • endometrial cancer

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer.'. Together they form a unique fingerprint.

Cite this